NCT06972901View on ClinicalTrials.gov

Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2027

Conditions

Crohn Disease (CD)Ileocolic ResectionPost-endoscopic Operative Reccurence

Interventions

BIOLOGICAL

Early faecal calprotectin dosage

An early dosage of faecal calprotectin will be done for the active arm group.

Trial Locations (7)

Unknown

CHU d'Amiens, Amiens

CHU de Clermont-Ferrand, Clermont-Ferrand

CHU de Lille, Lille

HCL, Lyon

AP-HM, Marseille

CHU de Montpellier, Montpellier

CHU de Toulouse, Toulouse

All Listed Sponsors

lead

University Hospital, Clermont-Ferrand

OTHER

NCT06972901 - Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin | Biotech Hunter | Biotech Hunter